Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,064 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
Yoshida T, Matsuzaki K, Kobayashi Y, Takeda K, Nakayama M, Arai Y, Kakimoto K, Nishimura K. Yoshida T, et al. Among authors: matsuzaki k. Int Urol Nephrol. 2012 Apr;44(2):479-85. doi: 10.1007/s11255-011-0044-5. Epub 2011 Aug 6. Int Urol Nephrol. 2012. PMID: 21822599
Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Yamamoto Y, Kinouchi T, Matsuzaki K, Kawamura N, Jingushi K, Kawashima A, Nagahara A, Ujike T, Uemura M, Imamura R, Morii E, Nonomura N. Hayashi T, et al. Among authors: matsuzaki k. Prostate. 2017 Oct;77(14):1383-1388. doi: 10.1002/pros.23398. Epub 2017 Aug 28. Prostate. 2017. PMID: 28845570
The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nishimura K, Nonomura N, Uemura M. Kato T, et al. Among authors: matsuzaki k. Int J Clin Oncol. 2021 May;26(5):954-961. doi: 10.1007/s10147-021-01872-5. Epub 2021 Jan 20. Int J Clin Oncol. 2021. PMID: 33471290
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nakai Y, Nakayama M, Nonomura N, Uemura M. Kato T, et al. Among authors: matsuzaki k. Anticancer Res. 2021 Nov;41(11):5811-5816. doi: 10.21873/anticanres.15398. Anticancer Res. 2021. PMID: 34732455
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N. Kato T, et al. Among authors: matsuzaki k. Int J Clin Oncol. 2022 Oct;27(10):1596-1604. doi: 10.1007/s10147-022-02215-8. Epub 2022 Jul 13. Int J Clin Oncol. 2022. PMID: 35831538
1,064 results